Table 3.
Treatments used after the initial 2-year study period
| Combination Therapy (n = 40) | Heparin-Warfarin and Dipyridamole Therapy (n = 34) | |
|---|---|---|
| Combination | ||
| with ACEI or ARB | 0 (0.0%) | 2 (5.9%) |
| without ACEI or ARB | 0 (0.0%) | 5 (14.7%) |
| Steroid and immunosuppressant | ||
| with ACEI or ARB | 3 (7.5%) | 0 (0.0%) |
| without ACEI or ARB | 0 (0.0%) | 1 (2.9%) |
| Steroid | ||
| with ACEI or ARB | 6 (15.0%) | 1 (2.9%) |
| without ACEI or ARB | 1 (2.5%) | 0 (0.0%) |
| ACEI or ARB (partly with anti-platelets and/or warfarin and/or Sairei-to) | 11 (27.5%) | 3 (8.8%) |
| Anti-platelets and/or warfarin and/or Sairei-to | 6 (15.0%) | 4 (11.8%) |
| Warfarin alone | 0 (0.0%) | 1 (2.9%) |
| Sairei-to alone | 6 (15.0%) | 4 (11.8%) |
| No treatment | 7 (17.5%) | 9 (26.5%) |
| Unknown | 0 (0.0%) | 4 (11.8%) |
Combination treatment included prednisolone, azathioprine, heparin-warfarin, and dipyridamole. The immunosuppressant used was azathioprine or mizoribine. Sairei-to is a Chinese herbal medicine.